nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GRIA3—adrenal cortex—adrenal gland cancer	0.0274	0.108	CbGeAlD
Lithium—IMPA1—gonad—adrenal gland cancer	0.0267	0.105	CbGeAlD
Lithium—GSK3A—adrenal cortex—adrenal gland cancer	0.0206	0.0812	CbGeAlD
Lithium—IMPA2—cardiac atrium—adrenal gland cancer	0.02	0.0788	CbGeAlD
Lithium—GRIA3—adrenal gland—adrenal gland cancer	0.0198	0.0779	CbGeAlD
Lithium—GSK3B—gonad—adrenal gland cancer	0.0197	0.0774	CbGeAlD
Lithium—IMPA2—pituitary gland—adrenal gland cancer	0.0195	0.0769	CbGeAlD
Lithium—IMPA2—adrenal gland—adrenal gland cancer	0.0175	0.0687	CbGeAlD
Lithium—GSK3B—adrenal gland—adrenal gland cancer	0.0171	0.0674	CbGeAlD
Lithium—GSK3A—gonad—adrenal gland cancer	0.0171	0.0673	CbGeAlD
Lithium—GSK3A—cardiac atrium—adrenal gland cancer	0.0171	0.0672	CbGeAlD
Lithium—GSK3A—pituitary gland—adrenal gland cancer	0.0167	0.0656	CbGeAlD
Lithium—GSK3A—adrenal gland—adrenal gland cancer	0.0149	0.0586	CbGeAlD
Lithium—GSK3A—Integrated Breast Cancer Pathway—BRAF—adrenal gland cancer	0.00144	0.00193	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—RB1—adrenal gland cancer	0.00143	0.00192	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—MEN1—adrenal gland cancer	0.00143	0.00192	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—BRAF—adrenal gland cancer	0.00142	0.00191	CbGpPWpGaD
Lithium—GSK3B—CDC42 signaling events—CTNNB1—adrenal gland cancer	0.00142	0.00191	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—RB1—adrenal gland cancer	0.00141	0.0019	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—RB1—adrenal gland cancer	0.0014	0.00187	CbGpPWpGaD
Lithium—GSK3B—LKB1 signaling events—TP53—adrenal gland cancer	0.0014	0.00187	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—CDC42—adrenal gland cancer	0.00139	0.00187	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—BAD—adrenal gland cancer	0.00139	0.00187	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—BAD—adrenal gland cancer	0.00139	0.00187	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—BAD—adrenal gland cancer	0.00139	0.00187	CbGpPWpGaD
Lithium—GSK3B—ErbB Signaling Pathway—EGFR—adrenal gland cancer	0.00139	0.00186	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—BAD—adrenal gland cancer	0.00138	0.00185	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—BAD—adrenal gland cancer	0.00137	0.00183	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—BAD—adrenal gland cancer	0.00136	0.00183	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—BRAF—adrenal gland cancer	0.00136	0.00182	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—BAD—adrenal gland cancer	0.00131	0.00176	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—REN—adrenal gland cancer	0.00131	0.00175	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—IGF1R—adrenal gland cancer	0.0013	0.00174	CbGpPWpGaD
Lithium—GSK3A—Constitutive PI3K/AKT Signaling in Cancer—EGFR—adrenal gland cancer	0.00129	0.00173	CbGpPWpGaD
Lithium—GSK3A—Immune System—SH3KBP1—adrenal gland cancer	0.00129	0.00173	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—BAD—adrenal gland cancer	0.00129	0.00173	CbGpPWpGaD
Lithium—GSK3B—AMER1 mutants destabilize the destruction complex—CTNNB1—adrenal gland cancer	0.00128	0.00171	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—BRAF—adrenal gland cancer	0.00127	0.0017	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—CDKN2A—adrenal gland cancer	0.00126	0.00169	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—BAD—adrenal gland cancer	0.00123	0.00165	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—BAD—adrenal gland cancer	0.00123	0.00165	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—BRAF—adrenal gland cancer	0.00123	0.00165	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—CTNNB1—adrenal gland cancer	0.00123	0.00165	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—CDKN2A—adrenal gland cancer	0.00123	0.00165	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PRKACA—adrenal gland cancer	0.00123	0.00164	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—BAD—adrenal gland cancer	0.00121	0.00163	CbGpPWpGaD
Lithium—GSK3B—LPA receptor mediated events—EGFR—adrenal gland cancer	0.00121	0.00162	CbGpPWpGaD
Lithium—GSK3B—Copper homeostasis—TP53—adrenal gland cancer	0.0012	0.00161	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—CDKN2A—adrenal gland cancer	0.00119	0.0016	CbGpPWpGaD
Lithium—GSK3A—Disease—SH3KBP1—adrenal gland cancer	0.00119	0.0016	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—PRKACA—adrenal gland cancer	0.00118	0.00159	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—BAD—adrenal gland cancer	0.00118	0.00158	CbGpPWpGaD
Lithium—GSK3B—Androgen receptor signaling pathway—CTNNB1—adrenal gland cancer	0.00117	0.00157	CbGpPWpGaD
Lithium—GSK3A—PI-3K cascade—EGFR—adrenal gland cancer	0.00116	0.00156	CbGpPWpGaD
Lithium—GSK3B—ErbB Signaling Pathway—TP53—adrenal gland cancer	0.00116	0.00156	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—BAD—adrenal gland cancer	0.00116	0.00156	CbGpPWpGaD
Lithium—GSK3B—Corticotropin-releasing hormone—CTNNB1—adrenal gland cancer	0.00114	0.00153	CbGpPWpGaD
Lithium—GSK3A—PI3K/AKT activation—EGFR—adrenal gland cancer	0.00114	0.00152	CbGpPWpGaD
Lithium—GSK3A—GAB1 signalosome—EGFR—adrenal gland cancer	0.00113	0.00151	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—BRAF—adrenal gland cancer	0.00112	0.00151	CbGpPWpGaD
Lithium—GSK3A—Disease—ZNRF3—adrenal gland cancer	0.00112	0.0015	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—BAD—adrenal gland cancer	0.00111	0.00149	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—BAD—adrenal gland cancer	0.0011	0.00148	CbGpPWpGaD
Lithium—GSK3A—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—adrenal gland cancer	0.0011	0.00148	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—BAD—adrenal gland cancer	0.0011	0.00147	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—BAD—adrenal gland cancer	0.00109	0.00147	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PRKACA—adrenal gland cancer	0.00109	0.00147	CbGpPWpGaD
Lithium—GSK3B—p53 pathway—TP53—adrenal gland cancer	0.00108	0.00145	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—BAD—adrenal gland cancer	0.00108	0.00145	CbGpPWpGaD
Lithium—GSK3B—Neural Crest Differentiation—CTNNB1—adrenal gland cancer	0.00106	0.00142	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—CTNNB1—adrenal gland cancer	0.00105	0.00141	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MED12—adrenal gland cancer	0.00105	0.00141	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—CTNNB1—adrenal gland cancer	0.00104	0.00139	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—BAD—adrenal gland cancer	0.00103	0.00138	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—BAD—adrenal gland cancer	0.00103	0.00138	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—BAD—adrenal gland cancer	0.00103	0.00138	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—BAD—adrenal gland cancer	0.00102	0.00137	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—BAD—adrenal gland cancer	0.00101	0.00136	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—BAD—adrenal gland cancer	0.00101	0.00135	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—BRAF—adrenal gland cancer	0.00101	0.00135	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—TERT—adrenal gland cancer	0.001	0.00134	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—CTNNB1—adrenal gland cancer	0.000998	0.00134	CbGpPWpGaD
Lithium—IMPA2—Metabolism—GNAS—adrenal gland cancer	0.000994	0.00133	CbGpPWpGaD
Lithium—IMPA2—Metabolism—ABCB1—adrenal gland cancer	0.000976	0.00131	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—BAD—adrenal gland cancer	0.000972	0.0013	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—TERT—adrenal gland cancer	0.00097	0.0013	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—PTGS2—adrenal gland cancer	0.000964	0.00129	CbGpPWpGaD
Lithium—GSK3B—Constitutive PI3K/AKT Signaling in Cancer—EGFR—adrenal gland cancer	0.000956	0.00128	CbGpPWpGaD
Lithium—GSK3B—Immune System—SH3KBP1—adrenal gland cancer	0.000954	0.00128	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—BAD—adrenal gland cancer	0.000952	0.00128	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—BAD—adrenal gland cancer	0.000949	0.00127	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—BRAF—adrenal gland cancer	0.000937	0.00126	CbGpPWpGaD
Lithium—GSK3B—Androgen receptor signaling pathway—EGFR—adrenal gland cancer	0.00093	0.00125	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PRKACA—adrenal gland cancer	0.000914	0.00123	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—BAD—adrenal gland cancer	0.000912	0.00122	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—CDC42—adrenal gland cancer	0.000909	0.00122	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—TERT—adrenal gland cancer	0.0009	0.00121	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GNRHR—adrenal gland cancer	0.000898	0.0012	CbGpPWpGaD
Lithium—IMPA1—Metabolism—GNAS—adrenal gland cancer	0.000886	0.00119	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—BRAF—adrenal gland cancer	0.000885	0.00119	CbGpPWpGaD
Lithium—GSK3B—Disease—SH3KBP1—adrenal gland cancer	0.000881	0.00118	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PRKACA—adrenal gland cancer	0.000878	0.00118	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—EGFR—adrenal gland cancer	0.000871	0.00117	CbGpPWpGaD
Lithium—IMPA1—Metabolism—ABCB1—adrenal gland cancer	0.00087	0.00117	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—BRAF—adrenal gland cancer	0.000864	0.00116	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	0.000862	0.00116	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—EGFR—adrenal gland cancer	0.000861	0.00115	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—TP53—adrenal gland cancer	0.000859	0.00115	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—EGFR—adrenal gland cancer	0.00084	0.00113	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000835	0.00112	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—EGFR—adrenal gland cancer	0.000834	0.00112	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—TP53—adrenal gland cancer	0.000834	0.00112	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—EGFR—adrenal gland cancer	0.000833	0.00112	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—BRAF—adrenal gland cancer	0.00083	0.00111	CbGpPWpGaD
Lithium—GSK3B—Disease—ZNRF3—adrenal gland cancer	0.000829	0.00111	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—EGFR—adrenal gland cancer	0.000824	0.0011	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—EGFR—adrenal gland cancer	0.00082	0.0011	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—adrenal gland cancer	0.000815	0.00109	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—CTNNB1—adrenal gland cancer	0.000799	0.00107	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ZNRF3—adrenal gland cancer	0.000785	0.00105	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—EGFR—adrenal gland cancer	0.000783	0.00105	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—EGFR—adrenal gland cancer	0.000779	0.00104	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—EGFR—adrenal gland cancer	0.000775	0.00104	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CDC42—adrenal gland cancer	0.000775	0.00104	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—EGFR—adrenal gland cancer	0.000772	0.00103	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—EGFR—adrenal gland cancer	0.000761	0.00102	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CDC42—adrenal gland cancer	0.000745	0.000998	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—TERT—adrenal gland cancer	0.000742	0.000995	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—EGFR—adrenal gland cancer	0.000726	0.000973	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—EGFR—adrenal gland cancer	0.000726	0.000973	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—EGFR—adrenal gland cancer	0.000726	0.000973	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—EGFR—adrenal gland cancer	0.000719	0.000964	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—EGFR—adrenal gland cancer	0.000713	0.000956	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—EGFR—adrenal gland cancer	0.00071	0.000952	CbGpPWpGaD
Lithium—GSK3A—Disease—SPRY2—adrenal gland cancer	0.000703	0.000942	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—BAD—adrenal gland cancer	0.000701	0.00094	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—TP53—adrenal gland cancer	0.0007	0.000938	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—TP53—adrenal gland cancer	0.0007	0.000938	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—TP53—adrenal gland cancer	0.000692	0.000928	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TP53—adrenal gland cancer	0.000684	0.000917	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	0.000683	0.000916	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PRKACA—adrenal gland cancer	0.000676	0.000905	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—EGFR—adrenal gland cancer	0.000672	0.000901	CbGpPWpGaD
Lithium—IMPA2—Metabolism—POMC—adrenal gland cancer	0.00067	0.000898	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—RB1—adrenal gland cancer	0.000669	0.000896	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—adrenal gland cancer	0.000664	0.00089	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GNRHR—adrenal gland cancer	0.000664	0.00089	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—IGF2—adrenal gland cancer	0.000653	0.000875	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CDC42—adrenal gland cancer	0.000649	0.00087	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PRKACA—adrenal gland cancer	0.000649	0.00087	CbGpPWpGaD
Lithium—GSK3A—Disease—MEN1—adrenal gland cancer	0.000644	0.000863	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—EGFR—adrenal gland cancer	0.000643	0.000863	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—EGFR—adrenal gland cancer	0.000643	0.000862	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—CTNNB1—adrenal gland cancer	0.00064	0.000858	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—BRAF—adrenal gland cancer	0.000638	0.000856	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000617	0.000827	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—EGFR—adrenal gland cancer	0.000616	0.000825	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—EGFR—adrenal gland cancer	0.000606	0.000812	CbGpPWpGaD
Lithium—IMPA1—Metabolism—POMC—adrenal gland cancer	0.000597	0.0008	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CDKN2A—adrenal gland cancer	0.000588	0.000788	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00058	0.000778	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—EGFR—adrenal gland cancer	0.000579	0.000776	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—EGFR—adrenal gland cancer	0.000576	0.000772	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	0.000574	0.000769	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—CTNNB1—adrenal gland cancer	0.000573	0.000768	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—EGFR—adrenal gland cancer	0.000573	0.000768	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CDC42—adrenal gland cancer	0.000573	0.000768	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—EGFR—adrenal gland cancer	0.00057	0.000764	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—EGFR—adrenal gland cancer	0.000562	0.000753	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—CTNNB1—adrenal gland cancer	0.000555	0.000744	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDC42—adrenal gland cancer	0.00055	0.000738	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—BAD—adrenal gland cancer	0.000541	0.000725	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GNRH1—adrenal gland cancer	0.000538	0.000721	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—EGFR—adrenal gland cancer	0.000536	0.000719	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—EGFR—adrenal gland cancer	0.000536	0.000719	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—EGFR—adrenal gland cancer	0.000536	0.000719	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PTGS2—adrenal gland cancer	0.000534	0.000716	CbGpPWpGaD
Lithium—GSK3A—Immune System—PRKACA—adrenal gland cancer	0.000532	0.000714	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—EGFR—adrenal gland cancer	0.000532	0.000713	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—EGFR—adrenal gland cancer	0.000527	0.000706	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—EGFR—adrenal gland cancer	0.000525	0.000703	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—BAD—adrenal gland cancer	0.00052	0.000697	CbGpPWpGaD
Lithium—GSK3B—Disease—SPRY2—adrenal gland cancer	0.000519	0.000696	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—CTNNB1—adrenal gland cancer	0.000515	0.000691	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—EGFR—adrenal gland cancer	0.000507	0.000679	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—EGFR—adrenal gland cancer	0.000496	0.000665	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—EGFR—adrenal gland cancer	0.000495	0.000663	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SPRY2—adrenal gland cancer	0.000492	0.00066	CbGpPWpGaD
Lithium—GSK3A—Disease—PRKACA—adrenal gland cancer	0.000492	0.000659	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TSHR—adrenal gland cancer	0.00048	0.000643	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PTGS2—adrenal gland cancer	0.000476	0.000638	CbGpPWpGaD
Lithium—GSK3B—Disease—MEN1—adrenal gland cancer	0.000476	0.000638	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—EGFR—adrenal gland cancer	0.000475	0.000637	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDC42—adrenal gland cancer	0.000452	0.000605	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MEN1—adrenal gland cancer	0.000451	0.000604	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—POMC—adrenal gland cancer	0.000436	0.000584	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—CTNNB1—adrenal gland cancer	0.000425	0.000569	CbGpPWpGaD
Lithium—GSK3A—Disease—CDC42—adrenal gland cancer	0.000417	0.000559	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—adrenal gland cancer	0.000407	0.000545	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—BAD—adrenal gland cancer	0.0004	0.000536	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GNRH1—adrenal gland cancer	0.000398	0.000533	CbGpPWpGaD
Lithium—GSK3B—Immune System—PRKACA—adrenal gland cancer	0.000393	0.000527	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—BAD—adrenal gland cancer	0.000384	0.000515	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—EGFR—adrenal gland cancer	0.000365	0.00049	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SPRY2—adrenal gland cancer	0.000364	0.000488	CbGpPWpGaD
Lithium—GSK3B—Disease—PRKACA—adrenal gland cancer	0.000363	0.000487	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CTNNB1—adrenal gland cancer	0.000356	0.000477	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TSHR—adrenal gland cancer	0.000354	0.000475	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PRKACA—adrenal gland cancer	0.000344	0.000461	CbGpPWpGaD
Lithium—GSK3A—Disease—TERT—adrenal gland cancer	0.000334	0.000448	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDC42—adrenal gland cancer	0.000334	0.000447	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MEN1—adrenal gland cancer	0.000333	0.000447	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—adrenal gland cancer	0.000331	0.000443	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—adrenal gland cancer	0.000327	0.000438	CbGpPWpGaD
Lithium—GSK3A—Immune System—BAD—adrenal gland cancer	0.000315	0.000422	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CTNNB1—adrenal gland cancer	0.000311	0.000417	CbGpPWpGaD
Lithium—GSK3B—Disease—CDC42—adrenal gland cancer	0.000308	0.000413	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CTNNB1—adrenal gland cancer	0.000298	0.000399	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDC42—adrenal gland cancer	0.000292	0.000391	CbGpPWpGaD
Lithium—GSK3A—Disease—BAD—adrenal gland cancer	0.000291	0.00039	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EGFR—adrenal gland cancer	0.000282	0.000378	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF2—adrenal gland cancer	0.000281	0.000377	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GNAS—adrenal gland cancer	0.000279	0.000374	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF1R—adrenal gland cancer	0.000272	0.000365	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—adrenal gland cancer	0.000271	0.000363	CbGpPWpGaD
Lithium—GSK3A—Disease—BRAF—adrenal gland cancer	0.000265	0.000355	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CTNNB1—adrenal gland cancer	0.000263	0.000353	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PRKACA—adrenal gland cancer	0.000254	0.000341	CbGpPWpGaD
Lithium—GSK3B—Disease—TERT—adrenal gland cancer	0.000247	0.000331	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—adrenal gland cancer	0.000236	0.000316	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TERT—adrenal gland cancer	0.000234	0.000314	CbGpPWpGaD
Lithium—GSK3B—Immune System—BAD—adrenal gland cancer	0.000233	0.000312	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDC42—adrenal gland cancer	0.000216	0.000289	CbGpPWpGaD
Lithium—GSK3B—Disease—BAD—adrenal gland cancer	0.000215	0.000288	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—adrenal gland cancer	0.000214	0.000287	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—adrenal gland cancer	0.000208	0.000279	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF2—adrenal gland cancer	0.000208	0.000279	CbGpPWpGaD
Lithium—GSK3A—Immune System—CTNNB1—adrenal gland cancer	0.000207	0.000278	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GNAS—adrenal gland cancer	0.000206	0.000276	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—BAD—adrenal gland cancer	0.000204	0.000273	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF1R—adrenal gland cancer	0.000201	0.00027	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—adrenal gland cancer	0.0002	0.000268	CbGpPWpGaD
Lithium—GSK3B—Disease—BRAF—adrenal gland cancer	0.000196	0.000262	CbGpPWpGaD
Lithium—GSK3A—Disease—CTNNB1—adrenal gland cancer	0.000191	0.000257	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—POMC—adrenal gland cancer	0.000188	0.000252	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—BRAF—adrenal gland cancer	0.000186	0.000249	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TERT—adrenal gland cancer	0.000173	0.000232	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—adrenal gland cancer	0.000164	0.00022	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—adrenal gland cancer	0.000158	0.000212	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTNNB1—adrenal gland cancer	0.000153	0.000205	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—adrenal gland cancer	0.000152	0.000203	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—BAD—adrenal gland cancer	0.000151	0.000202	CbGpPWpGaD
Lithium—GSK3B—Disease—CTNNB1—adrenal gland cancer	0.000141	0.00019	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—POMC—adrenal gland cancer	0.000139	0.000186	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—BRAF—adrenal gland cancer	0.000137	0.000184	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000134	0.00018	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—adrenal gland cancer	0.000121	0.000163	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—adrenal gland cancer	0.000112	0.00015	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—adrenal gland cancer	0.000106	0.000142	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CTNNB1—adrenal gland cancer	9.91e-05	0.000133	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—adrenal gland cancer	8.92e-05	0.00012	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—adrenal gland cancer	7.85e-05	0.000105	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—adrenal gland cancer	6.59e-05	8.83e-05	CbGpPWpGaD
